BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29849166)

  • 1. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
    Ho RW; Fang PC; Chao TL; Chien CC; Kuo MT
    Sci Rep; 2018 May; 8(1):8367. PubMed ID: 29849166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm.
    Bayraktar Bilen N; Bilen Ş; Topçu Yılmaz P; Evren Kemer Ö
    Int Ophthalmol; 2022 Aug; 42(8):2625-2632. PubMed ID: 35355169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
    Lolekha P; Choolam A; Kulkantrakorn K
    Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
    Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
    Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy.
    Alexandru H; Muthuraman M; Chirumamilla VC; Koirala N; Paktas B; Deuschl G; Zeuner KE; Groppa S
    PLoS One; 2016; 11(12):e0168652. PubMed ID: 27992533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
    Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin and blink rate in patients with blepharospasm and increased blinking.
    Ferrazzano G; Conte A; Fabbrini G; Bologna M; Macerollo A; Defazio G; Hallett M; Berardelli A
    J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):336-40. PubMed ID: 24963123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
    Park DI; Shin HM; Lee SY; Lew H
    Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
    Lu R; Huang R; Li K; Zhang X; Yang H; Quan Y; Li Q
    Am J Ophthalmol; 2014 Mar; 157(3):591-7.e1-2. PubMed ID: 24269849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relations between nonmotor manifestations and motor disorders in patients with benign essential blepharospasm.
    Zhou Y; Wang W; Lin Z; Lin T; Gong L
    Graefes Arch Clin Exp Ophthalmol; 2023 Dec; 261(12):3615-3623. PubMed ID: 37341835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Botulinum toxin type A influence on the lacrimal function of patients with facial dystonia].
    Oliveira FC; Oliveira GC; Cariello AJ; Felberg S; Osaki MH
    Arq Bras Oftalmol; 2010; 73(5):405-8. PubMed ID: 21225122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
    Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
    Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study.
    Pellegrini M; Schiavi C; Taroni L; Sebastiani S; Bernabei F; Roda M; Moscardelli F; Giannaccare G
    Indian J Ophthalmol; 2019 Sep; 67(9):1405-1409. PubMed ID: 31436182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of Hemorrhagic Side Effects of Botulinum Neurotoxin Treatment in Patients with Blepharospasm and Hemifacial Spasm on Antithrombotic Medication.
    Wenninger FC; Wabbels B
    Toxins (Basel); 2022 Nov; 14(11):. PubMed ID: 36356019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the injection botulinum toxin A in cases of blepharospasm syndrome, hemifacial spasm and Meige's syndrome.
    Bastola P; Chaudhary M; Agrawal JP; Shah DN
    Kathmandu Univ Med J (KUMJ); 2010; 8(31):305-10. PubMed ID: 22610735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment].
    Costa PG; Cardoso IP; Saraiva FP; Raiza AC; Tanaka LK; Matayoshi S
    Arq Bras Oftalmol; 2006; 69(3):319-22. PubMed ID: 16936952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the effects of Botulinum Toxin A on tear metrics in patients with hemifacial spasm.
    Mali YP; Schultze RL; Wladis EJ
    Orbit; 2017 Oct; 36(5):307-310. PubMed ID: 28627956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment.
    Xiao L; Pan Y; Zhang X; Hu Y; Cai L; Nie Z; Pan L; Li B; He Y; Jin L
    Neurol Sci; 2016 Nov; 37(11):1807-1813. PubMed ID: 27431279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
    Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
    Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.